Validated RP-HPLC method for the estimation of nebivolol hydrochloride and valsartan in combined tablet dosage form

The intention of this work is to develop a rapid, precise, accurate and sensitive reverse phase liquid chromatographic technique for the simultaneous estimation of Nebivolol and Valsartan in tablet dosage form. The chromatographic method was standardized using Inertsil ODS column (250x4.6mm, 5μm particle size) with UV detection at 278nm and flow rate of lml/min. The mobile phase comprises of ACN: Buffer (pH adjusted to 3.5 with dilute Ortho Phosphoric acid) in the fraction of 60:40 v/v. The linearity of proposed method was investigated in the range of 12.5-62.5μg/ml (R²=0.999) for Nebivolol and 200–1000μg/ml(R²=0.999) for Valsartan duly. The limit of detection (LOD) was found to be 0.05μg/ml and 0.81μg/ml for Nebivolol and Valsartan duly. The limit of quantification (LOQ) was found to be 0.15μg/ml and 2.44μg/ml for Nebivolol and Valsartan respectively. The retention time of Nebivolol and Valsartan were ground in to be 4.400min and 2.568min respectively. The method was authentically suggested and % RSD was ground in to be less than 2 indicating high degree of accuracy and precision. Hence proposed method can be successfully graded for the simultaneous estimation of Nebivolol and Valsartan in marketed formulation.